Skip to main content
Top of the Page

Submissions

Submissions are an important advocacy tool for COSA. We regularly respond to consultations on important issues for the cancer care community. We provide expert evidence-based input on behalf of our multidisciplinary community to help secure funding, and shape policy and legislation.

2023

Senate Standing Committee Equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer joint submission – 28 August 2023
MSAC application 1744 input from MOGA and COSA – 5 July 2023

2022

COSA Exercise Group Submission to Draft Australian Cancer Plan – 15 December 2022
COSA Geriatric Oncology Group Submission to Draft Australian Cancer Plan – 15 December 2022
DFAT New International Development Policy Submission from COSA – 30 November 2022
Telehealth phone call rebates must be permanently reinstated – A communique – 17 June 2022
Repurposing Medicines Follow up Consultation CCA COSA MOGA response – 1 April 2022
Submission from COSA Geriatric Oncology Group to Australian Cancer Plan 2023–2033 Consultation – March 2022

2019

ACSQHC National Clinical Trials Governance Framework Consultation COSA response – 29 March 2019

2018

MBS Review Taskforce Feedback on Draft Oncology Clinical Committee report – 20 July 2018
TGA Discussion Paper Communication plan on provisionally registered medicines CCA COSA submission – 9 July 2018
TGA Consultation Management and Communication of Medicines Shortages COSA CCA response – 23 April 2018

2017

Framework for NHMRC Assessment and Funding for Clinical trials and Cohort Studies CCA COSA Submission – July 2017
TGA Consultation Comparable overseas regulators – medical devices CCA COSA response – June 2017
TGA Consultation Provisional Approval pathway for prescription medicines CCA COSA response – 3 May 2017
Response to National Health Genomics Policy Framework 2017-2020 COSA CCA Submission – March 2017
NSW Health Consultation – Statewide Biobanking Consent COSA CCA Submission – February 2017

2016

TGA Consultation Comparable overseas regulators – prescription medicines CCA COSA response – December 2016
TGA Consultation Expedited pathways for prescription medicines CCA COSA response – December 2016
TGA Consultation Orphan drug program CCA COSA response – November 2016

2015

Biosimilar Awareness Implementation Framework CCA COSA Joint Submission – 30 October 2015
Chemotherapy Compounding Payments Scheme Draft Operational Guidelines COSA CPG CCA Submission – August 2015
TGA Consultation Orphan drug program discussion paper CCA COSA response – March 2015

Back to Top